EUCTR2018-002087-12-PL进行中（未招募）1 期
AN OPEN-LABEL STUDY OF RISDIPLAM IN INFANTS WITH GENETICALLY DIAGNOSED AND PRESYMPTOMATIC SPINAL MUSCULAR ATROPHY
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Males and females aged from birth (1 day) to 6 weeks (42 days) of age at the time of first dose (Day 1); a minimum age of 7 days at first dose is required for the first infant to be enrolled
- •- Gestational age of 37-42 weeks for singleton births; gestational age of 34-42 weeks for twins
- •- Body weight >= 3rd percentile for age, using appropriate country-specific guidelines
- •- Genetic diagnosis of 5q-autosomal recessive SMA, including confirmation of homozygous deletion or compound heterozygosity predictive of loss of function of the SMN1 gene
- •- Absence of clinical signs or symptoms at screening (Day -42 to Day -2) or at baseline (Day -1) that are, in the opinion of the investigator, strongly suggestive of SMA
- •- Receiving adequate nutrition and hydration at the time of screening, in the opinion of the investigator
- •- Adequately recovered from any acute illness at baseline and considered well enough to participate in the study, in the opinion of the investigator
- •- Able and expected to be able to safely travel to the study site for the entire duration of the study and in accordance to the frequency of required study visits, in the opinion of the investigator
- •- Able to complete all study procedures, measurements, and visits, and the parent (or caregiver), in the opinion of the investigator, has adequately supportive psychosocial circumstances
- •- Parent (or caregiver) is willing to consider nasogastric, naso-jejunal, or gastrostomy tube placement during the study to maintain safe hydration, nutrition, and treatment delivery, if recommended by the investigator
- •- Parent (or caregiver) is willing to consider the use of non-invasive ventilation during the study, if recommended by the investigator
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 25
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Concomitant or previous participation in any investigational drug or device study at any time
- •- Concomitant or previous administration of an SMN2-targeting antisense oligonucleotide, SMN2-splicing modifier, or gene therapy either in a clinical study or as part of medical care
- •- Presence of significant concurrent syndromes or diseases
- •- In the opinion of the investigator, inadequate venous or capillary blood access for the study procedures
- •- Requiring invasive ventilation, tracheostomy or awake non-invasive ventilation
- •- Awake hypoxemia (SaO2 < 95%) with or without ventilator support
- •- Multiple or fixed contractures and/or hip subluxation or dislocation at birth
- •- Systolic blood pressure or diastolic blood pressure or heart rate considered to be clinically significant by the investigator
- •- Presence of clinically relevant ECG abnormalities before study drug administration; corrected QT interval using Bazett’s method > 460 ms; personal or family history (first degree relatives) of congenital long QT syndrome indicating a safety risk for patients as determined by the investigator. First-degree atrioventricular block or isolated right bundle branch block are allowed
- •- The infant (and the mother, if breastfeeding the infant) taking any inhibitor of CYP3A4 taken within 2 weeks, any inducer of CYP3A4 taken within 4 weeks, any OCT 2 and MATE substrates within 2 weeks and known FMO1 or FMO3 inhibitors or substrates
- •- Clinically significant abnormalities in laboratory test results
- •- Ascertained or presumptive hypersensitivity to risdiplam or to the constituents of its formulation
- •- Treatment with oral salbutamol or another beta-2 adrenergic agonist taken orally for SMA is not allowed. Use of inhaled beta-2 adrenergic agonists is allowed
- •- Infants exposed to drugs with known retinal toxicity given to mothers during pregnancy (and lactation) should not be enrolled. Anticipated need for drugs known to cause retinal toxicity during the study.
- •- Diagnosis of ophthalmic diseases
研究者
相似试验
进行中（未招募）
1 期
A Study of Risdiplam in Infants with Genetically Diagnosed and Presymptomatic Spinal Muscular AtrophySpinal Muscular Atrophy (SMA)MedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.0Level: LLTClassification code 10079419Term: Spinal muscular atrophy pre-symptomaticSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-002087-12-BEF. Hoffmann-La Roche Ltd26
进行中（未招募）
1 期
A Study of Risdiplam in Infants with Genetically Diagnosed and Presymptomatic Spinal Muscular AtrophySpinal Muscular Atrophy (SMA)MedDRA version: 20.1Level: PTClassification code 10041582Term: Spinal muscular atrophySystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.0Level: LLTClassification code 10079419Term: Spinal muscular atrophy pre-symptomaticSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-002087-12-ITF. HOFFMANN - LA ROCHE LTD.25
进行中（未招募）
1 期
A Study of Risdiplam in Infants with Genetically Diagnosed and Presymptomatic Spinal Muscular AtrophySpinal Muscular Atrophy (SMA)MedDRA version: 20.0Level: LLTClassification code: 10079419Term: Spinal muscular atrophy pre-symptomatic Class: 10010331MedDRA version: 20.1Level: PTClassification code: 10041582Term: Spinal muscular atrophy Class: 100000004850CTIS2023-506009-20-00F. Hoffmann-La Roche AG26
招募中
2 期
efficacy evaluation of livergol in children with attention deficit hyperactivity disorderattention deficit hyperactivity disorder.Attention-deficit hyperactivity disordersIRCT20160813029327N22Islamic Azad University40
进行中（未招募）
1 期
A phase 2a Study in Infants with RSV lower respiratory tract infection, to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of RV521.Respiratory Syncytial Virus InfectionMedDRA version: 21.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-001010-15-HUReViral Ltd.184